Effect of Gevokizumab on Interleukin-1 β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes

ConclusionGevokizumab attenuates, but not abolishes, IL-1 β-mediated functional repression of CYP3A4 and drug transporters in human hepatocytes, which agrees with the fact that the mAb is considered as a modulator and not a blocker of IL-1β signaling. This attenuation of IL-1β-mediated down-regulation of hepatic detoxifying proteins by gevokizumab may h ave to be evaluated in terms of potential therapeutic protein drug–drug interactions when considering future development and therapeutic uses of this IL-1β neutralizing mAb.
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research